[HTML][HTML] New approaches to SCLC therapy: from the laboratory to the clinic

JT Poirier, J George, TK Owonikoko, A Berns… - Journal of Thoracic …, 2020 - Elsevier
The outcomes of patients with SCLC have not yet been substantially impacted by the
revolution in precision oncology, primarily owing to a paucity of genetic alterations in …

[HTML][HTML] PLK1 inhibition-based combination therapies for cancer management

S Su, G Chhabra, CK Singh, MA Ndiaye, N Ahmad - Translational oncology, 2022 - Elsevier
Polo-like kinase I (PLK1), a cell cycle regulating kinase, has been shown to have oncogenic
function in several cancers. Although PLK1 inhibitors, such as BI2536, BI6727 (volasertib) …

Mesoporous silica nanoparticles for the treatment of complex bone diseases: Bone cancer, bone infection and osteoporosis

M Gisbert-Garzarán, M Manzano, M Vallet-Regí - Pharmaceutics, 2020 - mdpi.com
Bone diseases, such as bone cancer, bone infection and osteoporosis, constitute a major
issue for modern societies as a consequence of their progressive ageing. Even though …

Non-proteolytic ubiquitylation in cellular signaling and human disease

Y Liao, I Sumara, E Pangou - Communications Biology, 2022 - nature.com
Ubiquitylation is one of the most common post-translational modifications (PTMs) of proteins
that frequently targets substrates for proteasomal degradation. However it can also result in …

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma

T Du, Y Song, A Ray, X Wan, Y Yao… - Blood, The Journal …, 2023 - ashpublications.org
PSMD4/Rpn10 is a subunit of the 19S proteasome unit that is involved with feeding target
proteins into the catalytic machinery of the 26S proteasome. Because proteasome inhibition …

N (6)-methyladenosine methylation-regulated polo-like kinase 1 cell cycle homeostasis as a potential target of radiotherapy in pancreatic adenocarcinoma

S Tatekawa, K Tamari, R Chijimatsu, M Konno… - Scientific reports, 2022 - nature.com
In pancreatic cancer, methyltransferase-like 3 (METTL3), a N (6)-methyladenosine (m6A)
methyltransferase, has a favorable effect on tumors and is a risk factor for patients' …

Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer

JM Stafford, MD Wyatt, C McInnes - Expert Opinion on Drug …, 2023 - Taylor & Francis
ABSTRACT Introduction Polo Like Kinase 1 (PLK1) is a key regulator of mitosis and its
overexpression is frequently observed in a wide variety of human cancers, while often being …

How microtubules build the spindle branch by branch

SM Travis, BP Mahon, S Petry - Annual review of cell and …, 2022 - annualreviews.org
The microtubule (MT) cytoskeleton provides the architecture that governs intracellular
organization and the regulated motion of macromolecules through the crowded cytoplasm …

Plk1 promotes renal tubulointerstitial fibrosis by targeting autophagy/lysosome axis

Y Du, Y Shang, Y Qian, Y Guo, S Chen, X Lin… - Cell Death & …, 2023 - nature.com
The prevalence of chronic kidney disease (CKD) has been increasing over the past
decades. However, no effective therapies are available for delaying or curing CKD …

Role of TSC1 in physiology and diseases

K Mallela, A Kumar - Molecular and cellular biochemistry, 2021 - Springer
Since its initial discovery as the gene altered in Tuberous Sclerosis Complex (TSC), an
autosomal dominant disorder, the interest in TSC1 (Tuberous Sclerosis Complex 1) has …